, Tracking Stock Market Picks
Enter Symbol:
Rating: OSIR

Osiris Therapeutics, Inc. (NASDAQ: OSIR) downgraded to Sell by Brean Capital

Tuesday,  Nov 17, 2015  8:25 AM ET by Dave Ficere

Brean Capital downgraded Osiris Therapeutics, Inc. (NASDAQ: OSIR) to Sell.
Previously Brean Capital rated Buy with price target $19 Osiris Therapeutics, Inc. (NASDAQ: OSIR) on 12/29/2014, when the stock price was $14.93.

Osiris Therapeutics, Inc. (Osiris) is a stem cell therapeutic company, focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The Company?s principal biologic drug candidate, Prochymal, is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease (GvHD), Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure, and is the only stem cell therapeutic granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (FDA). Its pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for osteoarthritis in the knee. In August 2009, the Company announced the creation of a new Biosurgery Division focused on developing and marketing high-end biological products for use in surgical procedures.

Brean Capital

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy